Vaccitech plc
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a VACC research report →
About the company
Vaccitech plc is a clinical-stage biopharmaceutical company focused on developing cutting-edge T-cell immunotherapeutics and vaccines. Their mission is to treat and prevent a variety of infectious diseases and cancers. The company's therapeutic pipeline includes several programs undergoing clinical evaluation: VTP-300 is in Phase 1/2a clinical trials for chronic hepatitis B.
- CEO
- William J. Enright MBA
- IPO
- 2021
- Employees
- 33
- HQ
- Oxford, GB
Price Chart
- Market Cap
- $192.73M
- P/E
- -0.48
- P/S
- 0.00
- P/B
- 0.38
- EV/EBITDA
- 0.65
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -63.87%
- ROIC
- -68.71%
- Revenue
- $0 · -100.00%
- Net Income
- $-66,428,000 · -8.77%
- EPS
- $-1.64 · -5.81%
- Op Income
- $506.00K
- FCF YoY
- -60.95%
- 52W High
- $5.10
- 52W Low
- $1.64
- 50D MA
- $3.14
- 200D MA
- $2.58
- Beta
- -0.27
- Avg Volume
- 731.88K
Get TickerSpark's AI analysis on VACC
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 2, 24 | Pelletier Nadege | other | 105,000 |
| Jan 2, 24 | Griffiths Graham | other | 96,500 |
| Jan 2, 24 | Enright William | other | 443,981 |
| Jan 2, 24 | Brown Gemma | other | 193,000 |
| Jun 26, 23 | Scheeren Joseph | buy | 10,000 |
| May 25, 23 | Wright Robin | buy | 13,750 |
| May 11, 23 | Wright Robin | other | 19,197 |
| May 11, 23 | Scheeren Joseph | other | 19,197 |
| May 11, 23 | Phillips Anne M. | other | 19,197 |
| May 11, 23 | Morgon Pierre A. | other | 19,197 |
Our VACC coverage
Recent articles, reports, and earnings notes.
No research on VACC yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate VACC report →Similar companies
Peers in the same neighborhood.